title: Molecular Imaging and Precision Medicine in Breast Cancer.
abstract: Precision medicine, basing treatment approaches on patient traits and specific molecular features of disease processes, has an important role in the management of patients with breast cancer as targeted therapies continue to improve. PET imaging offers noninvasive information that is complementary to traditional tissue biomarkers, including information about tumor burden, tumor metabolism, receptor status, and proliferation. Several PET agents that image breast cancer receptors can visually demonstrate the extent and heterogeneity of receptor-positive disease and help predict which tumors are likely to respond to targeted treatments. This review presents applications of PET imaging in the targeted treatment of breast cancer.
authors.affiliation: Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
authors.forename: Amy V
authors.initials: AV
authors.lastname: Chudgar
authors.affiliation: Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, University of Pennsylvania, Donner 116, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: david.mankoff@uphs.upenn.edu.
authors.forename: David A
authors.initials: DA
authors.lastname: Mankoff
mesh_terms: D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D005260:Female; D006801:Humans; D057054:Molecular Imaging; D058990:Molecular Targeted Therapy; D049268:Positron-Emission Tomography / Q000379:methods*; D057285:Precision Medicine; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals
chemical_list: D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals
keywords: 16α-[(18)F]fluoro-17β-estradiol (FES); Biomarkers; Breast cancer; Fluorodeoxyglucose (FDG); Precision medicine